E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Yuri B. Pride,Stephen D. Wiviott,Jacqueline L. Buros,Cafer Zorkun,M. Umer Tariq,Elliott M. Antman,Eugene Braunwald,C. Michael Gibson +7 more
TL;DR: Among ACS patients who underwent PCI without stent implantation, prasugrel therapy tended to reduce clinical ischemic events and to increase bleeding events to a similar magnitude as among patients who received stents.
Journal ArticleDOI
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction
Richard C. Becker,Christopher P. Cannon,Russell P. Tracy,Bruce Thompson,Edwin G. Bovill,Patrice Desvigne-Nickens,A.M.Y. Randall,Genell Knatternud,Eugene Braunwald +8 more
TL;DR: The Thrombolysis in Myocardial Ischemia III trial as mentioned in this paper showed that the optimal level of anticoagulation in this common clinical setting is between 45 and 60 seconds when heparin is included in the treatment strategy.
Journal ArticleDOI
Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack: Results from TRA 2°P-TIMI 50
Erin A. Bohula,Philip E. Aylward,Marc P. Bonaca,Ramón Corbalán,Róbert Gábor Kiss,Sabina A. Murphy,Benjamin M. Scirica,Harvey D. White,Eugene Braunwald,David A. Morrow +9 more
TL;DR: Vorapaxar reduced cardiovascular death, MI, or stroke in stable patients with a history of previous MI, whether treated concomitantly with a thienopyridine or not, and the relative risk of moderate or severe bleeding was similarly increased irrespective of thienobyridine use.
Journal ArticleDOI
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction.
Ajay J. Kirtane,Pedro Martinezclark,Aref Rahman,Kausik K. Ray,Dimitrios Karmpaliotis,Sabina A. Murphy,Robert P. Giugliano,Christopher P. Cannon,Elliott M. Antman,Matthew T. Roe,Robert A. Harrington,E. Magnus Ohman,Eugene Braunwald,C. Michael Gibson +13 more
TL;DR: To the Editor: ST-segment elevation myocardial infarction (STEMI) may arise from different pathophysiologic processes ranging from plaque rupture to endothelial surface erosion, and exposure of a denuded endothelium to a “high-risk blood phenotype” of elevated procoagulant is a possibility.